Analyzing...
Loading company...
KMS Medisurgi Ltd. engages in the manufacture of medical and surgical equipment. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-04-24. The firm manufactures and undertakes the job of coating various substrates, such as non-woven, polyurethane (PU) films, cotton fabrics, and taffeta silk fabrics with adhesive. The firm is engaged in the ethical marketing and distribution of surgical disposables, hemostats, medical devices, urology equipment, orthopedic/physiotherapy equipment, blood banking equipment and other such surgical equipment in India. Its product categories include transparent dressings, non-woven dressings, hydrocolloid dressings, surgical tapes, components, cast, incise film, beauty, and retail. Its surgical adhesive tape includes non-woven surgical tape with acrylic adhesive, surgical adhesive tapes, surgical paper tape, soft gel surgical tape, adhesive tape U.S.P, soft silicone tape, silk tape and foam tape. The company supplies its products both internationally and across India, and its manufacturing facility is located in Palghar.
Nothing flagged for monitoring
“Operates in Healthcare — Equipment & Devices.”
₹12 Cr revenue.
COGS 72.3%, employees 10.7%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 2.9%▼ | 8.6% |
| ROCE | 4.8%▼ | 12.6% |
| Net Margin | 2.0%▼ | 8.2% |
| EBITDA Margin | 7.4%▼ | 15.6% |
| Debt To Equity | 0.09x▼ | 0.11x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr -12.4% | ₹14 Cr +0.4% | ₹14 Cr +25.9% | ₹11 Cr +6.9% | ₹10 Cr +37.4% | ₹8 Cr -27.4% | ₹10 Cr +4.9% | ₹10 Cr |
| Other Income | ₹0.01 Cr -64.1% | ₹0.03 Cr -69.2% | ₹0.09 Cr +504.5% | ₹0.02 Cr -69.9% | ₹0.05 Cr -46.9% | ₹0.10 Cr ↑ Recovery | (₹0.00 Cr) ↓ Decline | ₹0.42 Cr |
| Total Income | ₹12 Cr -12.5% | ₹14 Cr -0.1% | ₹14 Cr +26.6% | ₹11 Cr +6.5% | ₹10 Cr +36.3% | ₹8 Cr -26.4% | ₹10 Cr +0.6% | ₹10 Cr |
| COGS | ₹9 Cr -16.4% | ₹11 Cr -1.8% | ₹11 Cr +35.8% | ₹8 Cr +1.6% | ₹8 Cr +35.0% | ₹6 Cr -27.2% | ₹8 Cr -1.2% | ₹8 Cr |
| ₹12 Cr -11.0% | ₹13 Cr -0.1% | ₹13 Cr +28.8% | ₹10 Cr +3.0% | ₹10 Cr +36.8% | ₹7 Cr -27.5% | ₹10 Cr +0.9% | ₹10 Cr | |
| Profit Before Tax | ₹0.33 Cr -45.9% | ₹0.61 Cr +1.0% | ₹0.60 Cr -8.3% | ₹0.66 Cr +131.0% | ₹0.29 Cr +20.1% | ₹0.24 Cr +30.0% | ₹0.18 Cr -13.1% | ₹0.21 Cr |
| ₹0.08 Cr -50.2% | ₹0.17 Cr +13.2% | ₹0.15 Cr +75.8% | ₹0.09 Cr +22.3% | ₹0.07 Cr -11.3% | ₹0.08 Cr +12.7% | ₹0.07 Cr -16.4% | ₹0.08 Cr | |
| Net Profit | ₹0.25 Cr -44.2% | ₹0.44 Cr -3.1% | ₹0.45 Cr -20.8% | ₹0.57 Cr +166.4% | ₹0.22 Cr +35.8% | ₹0.16 Cr +40.8% | ₹0.11 Cr -11.0% | ₹0.13 Cr |
| EPS | ₹0.74 | ₹1.33 | ₹1.38 | ₹1.74 | ₹0.65 | ₹0.48 | ₹0.34 | ₹0.38 |
| Diluted Shares | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr | ₹0.33 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Submission of Standalone audited financial results for the year ended 31 March, 2026
Submission of Standalone Audited financial result for the year ended 31.03.2026.
Meeting of the Board of Directors of the company will be held on Saturday, May 30, 2026, at 02.00 pm at the registered office of the company.
Mr. Pratik Pravin Tarpara has ceased to be an Independent Director of the company w.e.f. 30th September, 2025 upon completion of his tenure.
Non applicability of Regulation 24A of SEBI (LODR) Regulation, 2015.
Non applicability of report on CG.
Non applicability of Disclosure of related party transactions.
Closure of Trading Window
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.